Cardiovascular Systems Inc. (CSI) is comprised of a highly experienced,
uniquely qualified team of experts experienced in the assessment, development
and commercialization of medical devices for treating cardiovascular disease.
In 2004, CSI began developing "orbital" technology with the goal of
creating smooth, patent lumens in diseased vessels. In the years following,
the company refined the technology to address the growing market need of
providing a safer more effective atherectomy device, and the chance to shift the treatment
paradigm to improve the quality of life for the 12 million Americans who suffer from PAD.
Today, the Diamondback 360° Orbital Atherectomy System is protected by 20 patents
with 9 additional patents pending. The design, development and OASIS clinical trial testing is complete, with 510K clearance.
